Alpha Cognition Inc. Comm...

NASDAQ: ACOG · Real-Time Price · USD
8.00
0.00 (0.00%)
At close: Aug 15, 2025, 12:35 PM

Company Description

Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury.

It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases.

The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021.

Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.

Alpha Cognition Inc. Common Stock
Alpha Cognition Inc. Common Stock logo
Country CA
IPO Date n/a
Industry Financial - Conglomerates
Sector Financial Services
Employees 5
CEO Michael E. McFadden

Contact Details

Address:
750 West Pender Street
Vancouver, BC
CA
Website https://www.alphacognition.com

Stock Details

Ticker Symbol ACOG
Exchange NASDAQ
Fiscal Year n/a
Reporting Currency USD
CIK Code 0001655923
CUSIP Number n/a
ISIN Number CA02074J5017
Employer ID 00-0000000
SIC Code 2836

Key Executives

Name Position
Michael E. McFadden B.B.A. Chief Executive Officer & Director
Lauren D'Angelo M.B.A. Chief Operating Officer
Dr. Denis G. Kay Ph.D. Chief Scientific Officer
Kenneth Anthony Cawkell B.A., LL.B. Founder, Consultant, Corporate Secretary & Director

Latest SEC Filings

Date Type Title
Aug 14, 2025 10-Q Quarterly Report
Aug 05, 2025 424B3 Filing
Jul 21, 2025 S-3 Filing
Jul 17, 2025 424B3 Filing
Jul 01, 2025 S-3 Filing
Jun 23, 2025 8-K Current Report
May 15, 2025 10-Q Quarterly Report
May 06, 2025 DEFA14A Filing
May 06, 2025 DEFA14A Filing
Apr 30, 2025 DEF 14A Filing